From preventative to bioterrorism and therapeutic vaccines, AMR centers have mastered the art of vaccine research. Stellar performance in vaccine clinical trials has earned AMR a reputation of excellence across the industry.
In 2020, during the global Coronavirus pandemic, one AMR clinical research center – AMR Kansas City – was selected as one of the two first centers in the nation to conduct a COVID-19 Investigational Vaccine Clinical Research Study. Since then, AMR has worked tirelessly to obtain COVID-19 studies including vaccinations, diagnosis and treatment.
AMR is a three-time recipient of the World Vaccine Congress’s Vaccine Industry Excellence (ViE) Award for “Best Clinical Trial Site or Network” (2013, 2015, 2017) and was a finalist for this prestigious award in 2018. Vaccine clinical experience includes:
- 567 Vaccine Studies
- 62 Phase I Vaccine Studies
- 46 Vaccine Indications
- 47 Pharmaceutical and Bio-Tech Companies
- 35,039 Subjects Enrolled
- 136 percent Average Enrollment Goal Achieved
- 96 percent Average Retention Rate (for trials <6 months)
- Access to Infant, Pediatric, Adolescent, Adult, and Geriatric Populations
- Extensive Experience with Government Agencies Including BARDA, DMID, DoD, HHS, HRPO, NIAID, NIH, and the US Army
AMR centers are fully equipped to conduct complex vaccine trials with precision. Specific capabilities and certifications include:
- Local PBMC Processing
- Established Local IBC Committees
- Biosafety Level I & II Certifications
- Sterile Drug Preparation Environments
- Federal Wide Assurance (FWA) Numbers
- Overnight Stay Capabilities
- Proficient Pharmacy Teams Experienced in Complex Vaccine Preparation and Administration